Expats in Spain are concerned about the delay of a “historic” cholesterol-lowering medicine.


Expats in Spain are concerned about the delay of a “historic” cholesterol-lowering medicine.

EXPATS in Spain are worried about the new cholesterol-lowering medicine Leqvio and whether it will be accessible soon in their country.

After the NHS announced that it would be administering Leqvio to qualified patients, expats in Spain are allegedly concerned about its unavailability. Patients with heart and circulatory disorders will be provided the “landmark” partnership as an add-on therapy for those whose cholesterol levels do not respond properly to statins.

The NHS confirmed earlier this week that Leqvio would be available in the UK.

The European Union approved Leqvio, a cholesterol-lowering medication, for use last year.

According to euroweeklynews.com, several expats are concerned about when the medicine will be available in Spain.

It comes as Novartis, the firm behind Leqvio, has recently shifted the drug’s manufacturing to Austria.

Following the approval of Leqvio by the healthcare organization NICE, Novartis has reached an agreement with the NHS.

According to the business, nearly 300,000 individuals at high risk of a cardiovascular event will be treated with the medicine over the following three years.

In addition, the drug is part of a larger strategy in the United Kingdom to combat cardiovascular disease.

Heart and circulation disease affects around 7.6 million people in the United Kingdom.

According to the British Heart Foundation, this results in more than a quarter of all deaths each year.

“Cardiovascular disease has long been the leading cause of death in humans, and this persistent health problem necessitates a reinvention of how we treat heart health,” Novartis CEO Vas Narasimhan said in a statement.

He went on to say, “This ground-breaking collaboration with the NHS in England has the potential to inspire a step-change improvement in cardiovascular health across the UK.”

NHS England will identify high-risk patients, provide treatment, and track outcomes as part of the “groundbreaking” cooperation.

Leqvio “functions in a different way,” according to NICE.

“It’s the first of a new class of cholesterol-lowering drugs that uses RNA interference (RNAi) to increase the liver’s ability to eliminate bad cholesterol from the blood.”

Leqvio is “ripe and ready” for a “population-health strategy” as a fast-acting drug that will be injected twice a year to target “bad cholesterol.”

It’s an additional treatment option for those patients. “Brinkwire News in Condensed Form.”


Comments are closed.